Is Ascendis Pharma Stock a Good Investment?
Ascendis Pharma Investment Advice | ASND |
- Examine Ascendis Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Ascendis Pharma's leadership team and their track record. Good management can help Ascendis Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Ascendis Pharma's business and its evolving consumer preferences.
- Compare Ascendis Pharma's performance and market position to its competitors. Analyze how Ascendis Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if Ascendis Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Ascendis Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Ascendis Pharma AS stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ascendis Pharma AS is a good investment.
Sell | Buy |
Strong Buy
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Ascendis Pharma Stock
Researching Ascendis Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 7.12. Ascendis Pharma AS had not issued any dividends in recent years.
To determine if Ascendis Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ascendis Pharma's research are outlined below:
| Ascendis Pharma AS had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 363.64 M. Net Loss for the year was (378.08 M) with profit before overhead, payroll, taxes, and interest of 319.38 M. | |
| Ascendis Pharma AS currently holds about 955.15 M in cash with (306.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Biotech designed to commercialize Ascendis endocrinology drugs in China files 86M IPO - FiercePharma |
Ascendis Pharma Quarterly Gross Profit |
|
Ascendis Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ascendis Pharma AS. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ascendis Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Ascendis Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Ascendis Pharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-05-23 | 2017-03-31 | -0.75 | -0.83 | -0.08 | 10 | ||
2016-04-14 | 2016-03-31 | -0.46 | -0.54 | -0.08 | 17 | ||
2016-08-31 | 2016-06-30 | -0.69 | -0.6 | 0.09 | 13 | ||
2018-03-28 | 2017-12-31 | -0.8 | -0.92 | -0.12 | 15 | ||
2016-11-30 | 2016-09-30 | -0.68 | -0.8 | -0.12 | 17 | ||
2022-05-11 | 2022-03-31 | -2 | -2.21 | -0.21 | 10 | ||
2015-08-24 | 2015-06-30 | -0.49 | -0.7 | -0.21 | 42 | ||
2017-08-18 | 2017-06-30 | -0.72 | -0.94 | -0.22 | 30 |
Know Ascendis Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ascendis Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ascendis Pharma AS backward and forwards among themselves. Ascendis Pharma's institutional investor refers to the entity that pools money to purchase Ascendis Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Amvescap Plc. | 2024-12-31 | 1.2 M | Citadel Advisors Llc | 2024-12-31 | 896 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 825.8 K | Camber Capital Management Llc | 2024-12-31 | 800 K | Fidelity International Ltd | 2024-12-31 | 729.3 K | Wellington Management Company Llp | 2024-12-31 | 704.2 K | Ameriprise Financial Inc | 2024-12-31 | 702.6 K | Blackrock Inc | 2024-12-31 | 653.3 K | Goldman Sachs Group Inc | 2024-12-31 | 530.4 K | Ra Capital Management, Llc | 2024-12-31 | 10.1 M | Westfield Capital Management Company, L.p. | 2024-12-31 | 5.5 M |
Ascendis Pharma's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.97 B.Market Cap |
|
Ascendis Pharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (1.03) | (0.97) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | 3.58 | 3.76 |
Determining Ascendis Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Ascendis Pharma is a good buy. For example, gross profit margin measures Ascendis Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ascendis Pharma's profitability and make more informed investment decisions.
Ascendis Pharma's Earnings Breakdown by Geography
Please note, the presentation of Ascendis Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ascendis Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ascendis Pharma's management manipulating its earnings.
Evaluate Ascendis Pharma's management efficiency
Ascendis Pharma AS has return on total asset (ROA) of (0.1738) % which means that it has lost $0.1738 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.1843) %, meaning that it created substantial loss on money invested by shareholders. Ascendis Pharma's management efficiency ratios could be used to measure how well Ascendis Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 3.76, whereas Return On Tangible Assets are forecasted to decline to (0.34). At present, Ascendis Pharma's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 1.1 B, whereas Other Current Assets are forecasted to decline to about 16.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.84) | (1.75) | |
| Tangible Book Value Per Share | (1.91) | (1.82) | |
| Enterprise Value Over EBITDA | (27.31) | (25.95) | |
| Price Book Value Ratio | (72.12) | (68.52) | |
| Enterprise Value Multiple | (27.31) | (25.95) | |
| Price Fair Value | (72.12) | (68.52) | |
| Enterprise Value | 7.9 B | 8.3 B |
Leadership effectiveness at Ascendis Pharma AS is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 0.612 |
Basic technical analysis of Ascendis Stock
As of the 24th of March, Ascendis Pharma shows the risk adjusted performance of 0.1192, and Mean Deviation of 2.49. Ascendis Pharma AS technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Ascendis Pharma AS information ratio, and the relationship between the downside deviation and value at risk to decide if Ascendis Pharma AS is priced correctly, providing market reflects its regular price of 166.07 per share. Given that Ascendis Pharma has jensen alpha of 0.4915, we suggest you to validate Ascendis Pharma AS's prevailing market performance to make sure the company can sustain itself at a future point.Ascendis Pharma's Outstanding Corporate Bonds
Ascendis Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ascendis Pharma AS uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ascendis bonds can be classified according to their maturity, which is the date when Ascendis Pharma AS has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ASCENSION HEALTH Corp BondUS04352EAA38 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US04352EAB11 Corp BondUS04352EAB11 | View | |
| ASCENSION HEALTH ALLIANCE Corp BondUS04351LAB62 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Ascendis Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Ascendis Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1192 | |||
| Market Risk Adjusted Performance | 0.3894 | |||
| Mean Deviation | 2.49 | |||
| Semi Deviation | 2.24 | |||
| Downside Deviation | 2.51 | |||
| Coefficient Of Variation | 793.27 | |||
| Standard Deviation | 3.39 | |||
| Variance | 11.5 | |||
| Information Ratio | 0.143 | |||
| Jensen Alpha | 0.4915 | |||
| Total Risk Alpha | 0.6749 | |||
| Sortino Ratio | 0.1928 | |||
| Treynor Ratio | 0.3794 | |||
| Maximum Drawdown | 18.15 | |||
| Value At Risk | (3.90) | |||
| Potential Upside | 5.86 | |||
| Downside Variance | 6.32 | |||
| Semi Variance | 5.01 | |||
| Expected Short fall | (2.90) | |||
| Skewness | 1.29 | |||
| Kurtosis | 2.66 |
| Risk Adjusted Performance | 0.1192 | |||
| Market Risk Adjusted Performance | 0.3894 | |||
| Mean Deviation | 2.49 | |||
| Semi Deviation | 2.24 | |||
| Downside Deviation | 2.51 | |||
| Coefficient Of Variation | 793.27 | |||
| Standard Deviation | 3.39 | |||
| Variance | 11.5 | |||
| Information Ratio | 0.143 | |||
| Jensen Alpha | 0.4915 | |||
| Total Risk Alpha | 0.6749 | |||
| Sortino Ratio | 0.1928 | |||
| Treynor Ratio | 0.3794 | |||
| Maximum Drawdown | 18.15 | |||
| Value At Risk | (3.90) | |||
| Potential Upside | 5.86 | |||
| Downside Variance | 6.32 | |||
| Semi Variance | 5.01 | |||
| Expected Short fall | (2.90) | |||
| Skewness | 1.29 | |||
| Kurtosis | 2.66 |
Consider Ascendis Pharma's intraday indicators
Ascendis Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ascendis Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ascendis Pharma Corporate Filings
6K | 20th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 27th of February 2025 Other Reports | ViewVerify | |
| 14th of February 2025 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Ascendis Stock media impact
Far too much social signal, news, headlines, and media speculation about Ascendis Pharma that are available to investors today. That information is available publicly through Ascendis media outlets and privately through word of mouth or via Ascendis internal channels. However, regardless of the origin, that massive amount of Ascendis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ascendis Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ascendis Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ascendis Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ascendis Pharma alpha.
Ascendis Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Ascendis Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ascendis Pharma AS Historical Investor Sentiment
Investor biases related to Ascendis Pharma's public news can be used to forecast risks associated with an investment in Ascendis. The trend in average sentiment can be used to explain how an investor holding Ascendis can time the market purely based on public headlines and social activities around Ascendis Pharma AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ascendis Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ascendis Pharma and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ascendis Pharma news discussions. The higher the estimate score, the more favorable the investor's outlook on Ascendis Pharma.
Ascendis Pharma Maximum Pain Price Across June 20th 2025 Option Contracts
Ascendis Pharma's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Ascendis Pharma close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Ascendis Pharma's options.
Ascendis Pharma Corporate Management
| Michael LLM | Chief VP | Profile | |
| Birgitte MD | Sr Affairs | Profile | |
| Stina MD | Executive Oncology | Profile | |
| Scott Holmes | Head Endocrinology | Profile | |
| Timothy Lee | Director Relations | Profile | |
| Nyssa Noyola | Vice Management | Profile | |
| Jens Okkels | VP Devel | Profile |
Already Invested in Ascendis Pharma AS?
The danger of trading Ascendis Pharma AS is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Ascendis Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Ascendis Pharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Ascendis Pharma AS is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.12) | Revenue Per Share | Quarterly Revenue Growth 0.263 | Return On Assets | Return On Equity |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Ascendis Pharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.